Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod

Modern Rheumatology

Volumn 26, Issue 2, 2016, Pages 169-174

  Yoshioka, Yutaka ^a   Takahashi, Nobunori ^a   Kaneko, Atsushi ^b   Hirano, Yuji ^c   Kanayama, Yasuhide ^d   Kanda, Hiroyasu ^b   Takagi, Hideki ^e   Ito, Takayasu ^f   Kato, Takefumi ^g   Saito, Kiwamu ^h   Funahashi, Koji ^a   Asai, Shuji ^a   Takemoto, Toki ^a   Terabe, Kenya ^a   Asai, Nobuyuki ^a   Ishiguro, Naoki ^a   Kojima, Toshihisa ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b Nagoya Medical Centre   (Japan)

^c TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^d Department of Clinical Laboratory   (Japan)

^e NAGOYA CENTRAL HOSPITAL   (Japan)

^f Ito Orthopaedic Hospital   (Japan)

^g Kato Orthopaedic Clinic   (Japan)

^h Saito Clinic   (Japan)

Author keywords

Adequate observation period; Iguratimod; Japanese; Predictors; Rheumatoid arthritis

Indexed keywords

IGURATIMOD; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; STROMELYSIN; ANTIRHEUMATIC AGENT; CHROMONE DERIVATIVE; SULFONAMIDE;

AGED; ARTICLE; BRAIN HEMORRHAGE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOW DISEASE ACTIVITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; STOMACH ULCER; TENDER JOINT COUNT; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; MIDDLE AGED; REGISTER; REMISSION; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; CHROMONES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGISTRIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84959535219     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1069475     Document Type: Article

References (19)

1. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73(3): 492-509.
2. O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL Jr., Ranganath VK, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013; 65(8): 1985-94.
3. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013; 369(4): 307-18.
4. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallelgroup Swefot trial. Lancet. 2012; 379(9827): 1712-20.
5. Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaB alpha degradation. Inflamm Res. 2002; 51(4): 188-94.
6. Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med. 1999; 133(6): 566-74.
7. Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol. 2001; 28(12): 2591-6.
8. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured Bcells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford). 2003; 42(11): 1365-71.
9. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol. 2007; 17(1): 10-6.
10. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol. 2007; 17(1): 1-9.
11. Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014; 24(3): 410-8.
12. Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013; 23(3): 430-9.
13. Okamura K, Yonemoto Y, Okura C, Kobayashi T, Takagishi K. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol. 2015; 25(2): 235-40. doi:10.310 9/14397595.2014.938401.
14. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther. 2006; 8(4): R112.
15. Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, et al. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study. Rheumatology (Oxford). 2015; 54(5): 854-9. doi:10.1093/rheumatology/keu418.
16. van der Heijde D, Keystone EC, Curtis JR, Landewe RB, Schiff MH, Khanna D, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol. 2012; 39(7): 1326-33.
17. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, et al. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study. Mod Rheumatol. 2012; 22(3): 339-45.
18. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol. 2012; 22(3): 370-5.
19. Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015. 74(6): 1037-44. doi:10.1136/annrheumdis-2013-204769.